Journal article

Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women A Swedish Population Register-Based Cohort Study

Roxanne Hastie, Lina Bergman, Catherin A Cluver, Anna Wikman, Natalie J Hannan, Susan P Walker, Anna-Karin Wikstrom, Stephen Tong, Susanne Hesselman

HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019

Abstract

Preeclampsia is a hypertensive disorder of pregnancy characterized by maternal endothelial dysfunction and end-organ damage. The antiangiogenic factor, sFlt-1 (soluble FMS-like tyrosine kinase-1) has been strongly implicated in the pathogenesis of preeclampsia. sFlt-1 is secreted into the maternal circulation where it antagonizes VEGF (vascular endothelial growth factor) and ultimately disrupts vascular homeostasis. However, the upstream mechanisms regulating release of sFlt-1 are poorly characterized. We investigated the roles of key prosurvival pathways, EGFR (epidermal growth factor receptor) signaling, and the mitochondria, in regulating sFlt-1 production. We initially found that the mRN..

View full abstract

Grants

Awarded by National Health and Medical Research Council Fellowships


Funding Acknowledgements

R. Hastie was supported by a Melbourne Medical School, Department of Obstetrics and Gynaecology Fellowship; S. Tong (No. 1136418), F. Brownfoot (No. 1142636), and N.J. Hannan (No. 1146128) were supported by National Health and Medical Research Council Fellowships. L. Bergman and S. Hesselman were supported via a postdoc position at Center for clinical research, Falun, Sweden. The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.